XBI has nearly 50 points of upside to reach its previous all-time high, and 2026 biotech industry conditions may help it get ...
While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...
The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.
Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...
The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results